AKTX AKARI THERAPEUTICS PLC revenue, earnings and financials
For the quarter ended June 30, 2026, AKARI THERAPEUTICS PLC reported revenue of n/a, net income of −$4.81M and diluted EPS of $0.00; for the fiscal year ended December 2025 revenue was n/a.
AKTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$17.3M, net income −$17.3M (margin n/a), EPS $0.00
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$21.6M, net income −$19.8M (margin n/a), EPS $0.00
- Fiscal year ended Dec 2023: revenue $368K, gross profit n/a, operating income −$16.8M, net income −$10.0M (margin -2720.5%), EPS $0.00
- Fiscal year ended Dec 2022: revenue $608K, gross profit n/a, operating income −$11.8M, net income −$13.1M (margin -2153.9%), EPS −$0.74
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$17.2M, net income −$17.4M (margin n/a), EPS $0.00
AKTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.81M, EPS $0.00
- Quarter ended Mar 31, 2026: revenue n/a, net income −$14.5M, EPS $0.00
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$5.30M, EPS $0.00
- Quarter ended Sep 30, 2025: revenue n/a, net income −$6.40M, EPS $0.00
- Quarter ended Jun 30, 2025: revenue n/a, net income −$1.90M, EPS $0.00
- Quarter ended Mar 31, 2025: revenue n/a, net income −$3.71M, EPS $0.00
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$3.78M, EPS $0.00
- Quarter ended Sep 30, 2024: revenue n/a, net income −$2.90M, EPS $0.00
- Quarter ended Jun 30, 2024: revenue $0, net income −$7.56M, EPS $0.00
- Quarter ended Mar 31, 2024: revenue n/a, net income −$5.57M, EPS $0.00
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$4.14M, EPS $0.29
- Quarter ended Sep 30, 2023: revenue n/a, net income −$2.87M, EPS $0.00
- Quarter ended Jun 30, 2023: revenue $0, net income −$4.00M, EPS −$0.29
- Quarter ended Mar 31, 2023: revenue n/a, net income $1.00M, EPS $0.00
- Quarter ended Jun 30, 2022: revenue n/a, net income −$5.68M, EPS $0.00
- Quarter ended Jun 30, 2021: revenue n/a, net income −$4.35M, EPS $0.00
AKTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$10.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$12.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$16.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$7.49M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$18.8M, share buybacks n/a
AKTX balance sheet
- Jun 30, 2026: cash $7.69M, total assets $38.6M, total liabilities $20.0M, shareholders' equity $18.6M
- Mar 31, 2026: cash $2.77M, total assets $33.9M, total liabilities $19.5M, shareholders' equity $14.4M
- Dec 31, 2025: cash $5.20M, total assets $47.9M, total liabilities $19.6M, shareholders' equity $28.3M
- Sep 30, 2025: cash n/a, total assets $45.4M, total liabilities $22.7M, shareholders' equity $22.7M
- Jun 30, 2025: cash $2.71M, total assets $50.9M, total liabilities $25.3M, shareholders' equity $25.6M
- Mar 31, 2025: cash $2.58M, total assets $51.0M, total liabilities $29.2M, shareholders' equity $21.7M
- Dec 31, 2024: cash $0, total assets $50.6M, total liabilities $28.3M, shareholders' equity $22.2M
- Sep 30, 2024: cash $2.25M, total assets $2.73M, total liabilities n/a, shareholders' equity −$6.69M
Is AKTX profitable?
No. AKARI THERAPEUTICS PLC lost $31.0M over the last four quarters.
What is AKTX's EPS?
Diluted earnings per share over the last four quarters were $0.00; $0.00 in the latest quarter.